Big problem: no solution?

Article

Glaucoma is an important public-health problem in Europe, yet no public health approach exists for its detection and control, according to Tarek Shaarawy and K. Mansouri from the Hopitaux Universitaires de Genève, Switzerland.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
Related Content
The logo for Eye2Gene, an artificial-intelligence powered ophthalmology diagnostic platform for inherited retinal disease, shows DNA helix imagery and an eye. Image credit: Heidelberg Engineering

AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease

Abigail Lewis, editorial intern
July 18th 2025
Article

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy?

Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy?

July 17th 2025
Article
PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A row of beakers with yellow and orange fluid in a laboratory. Concept image for microbial lutein production, bioengineering, sustainable synthesis for cataract cornea age-related macular degeneration (AMD) and retinal disease. Image credit: bidala – stock.adobe.com

New microbial strain produces high yields of lutein for AMD, cataract prevention

Kassi Filkins
July 15th 2025
Article

Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Lynda Charters
July 13th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.